Home › Dermatomyositis › NCT07486869

Emapalumab MDA5 Rapidly Progressive Interstitial Lung Disease (RP-ILD) Study

Emapalumab for the Treatment of Anti-MDA5 Antibody Positive Rapidly Progressive Interstitial Lung Disease

Who can join

Ages 18 and older · All sexes

Inclusion Criteria:

* Progressive interstitial lung disease as determined by at least 2/4 of the following:

  1. worsening respiratory symptoms;
  2. worsening or new oxygen requirement;
  3. worsening disease on CT chest;
  4. worsening Forced Vital Capacity (FVC1) or Diffusing Capacity for Carbon Monoxide (DLCO) on pulmonary function tests
* MDA5 antibodies present
* Elevated ferritin above the upper limit of normal (ULN)
* Participant at least 18 years old

Exclusion Criteria:

* Active, untreated bacterial, mycobacterial or fungal infection
* Active herpes zoster infection
* Currently requiring extracorporeal membrane oxygenation (ECMO)
* Participant refusal to participate in the study
* Pregnant women
* Prisoners

About the study

This is a proof of concept study to determine if Emapalumab appears effective for the treatment of anti-MDA5 antibody positive rapidly progressive interstitial lung disease (MDA5 RP-ILD). Emapalumab is a medication that is currently used for a severe problem with the immune system, called macrophage activation syndrome, and this disease shares some similar features with MDA5 RP-ILD.

What is being tested

• Emapalumab (drug)

Sponsor: University of Miami · Participants: 5 · Started: Jul 23, 2026

Contact the study team

• Kelly Corbitt, D.O. · Phone: 305-243-7545

Official record on ClinicalTrials.gov — NCT07486869

Locations in the U.S.

Conditions

• Dermatomyositis
• Interstitial Lung Diseases

From ClinicalTrials.gov, data retrieved Sep 30, 2026. Each study sets its own eligibility; the study team decides who can join.